95 related articles for article (PubMed ID: 17953364)
21. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
22. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy.
Kawata A; Hosokawa M; Sawamura Y; Ito K; Une Y; Shibata T; Uchino J; Kobayashi H
Mol Biother; 1990 Dec; 2(4):221-7. PubMed ID: 2288722
[TBL] [Abstract][Full Text] [Related]
23. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Wang C; Chai L; Zhu G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
Belova OB; Vinnichuk UD; Shlakhovenko VA; Berezhnaya NM
Exp Oncol; 2007 Dec; 29(4):272-6. PubMed ID: 18199982
[TBL] [Abstract][Full Text] [Related]
25. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
26. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
27. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor activity of adherent LAK cells (A-LAK) in a model of squamous carcinoma of the head and neck].
Sacchi M; Galeazzi E; Johnson JT; Cavalot AL; Cortesina G
Acta Otorhinolaryngol Ital; 1991; 11(4):405-15. PubMed ID: 1792895
[TBL] [Abstract][Full Text] [Related]
29. [Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
Zhang Q; Wan Y; Zhai H
Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):355-7. PubMed ID: 10806675
[TBL] [Abstract][Full Text] [Related]
30. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
31. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice.
Hu W; Wang J; Dou J; He X; Zhao F; Jiang C; Yu F; Hu K; Chu L; Li X; Gu N
Cell Transplant; 2011; 20(5):669-80. PubMed ID: 21054951
[TBL] [Abstract][Full Text] [Related]
32. Analysis of lymphokine-activated killer (LAK) cells.
Ortaldo JR
Prog Clin Biol Res; 1987; 244():197-206. PubMed ID: 2443928
[No Abstract] [Full Text] [Related]
33. [Comparison of antitumor activity of tumor draining lymph node lymphocytes and peripheral blood lymphocytes in human oral cancer].
Guo W; Qiu WL; He RG
Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Nov; 29(6):336-8, 384. PubMed ID: 7743875
[TBL] [Abstract][Full Text] [Related]
34. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
36. [Experimental study on the treatment of human hepatocellular carcinoma by fibroblast-mediated human IFN-alpha gene therapy in combination with adoptive chemoimmunotherapy].
Wang J; Cao X; Kong X
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):266-70. PubMed ID: 7587892
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
39. [Cytotoxicity of lymphokine-activated killer cells in conjunction with pingyangmycin to human tongue carcinoma (Tca8113) in vitro and vivo].
Duan JG
Zhonghua Kou Qiang Yi Xue Za Zhi; 1993 Jul; 28(4):231-3. PubMed ID: 7513629
[No Abstract] [Full Text] [Related]
40. Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.
Kang SG; Ryu CH; Jeun SS; Park CK; Shin HJ; Kim JH; Kim MC; Kang JK
Childs Nerv Syst; 2004 Mar; 20(3):154-62. PubMed ID: 14968374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
